Small molecule drugs refer to drugs with relatively small molecular weight, usually composed of hundreds of atoms. They are a common class of medications that are often given to patients, either by mouth or by injection, to treat a variety of illnesses and conditions. Small molecule drugs can achieve therapeutic effects by interacting with molecules in organisms and affecting the biochemical processes of cells.

Small molecule drugs are usually prepared by chemical synthesis, and their molecular structures are precise and complex. They can modulate physiological processes by interacting with target proteins, such as enzymes, receptors, or other biomolecules, thereby achieving therapeutic goals. These drugs can be used to treat a variety of diseases, including infections, cancer, cardiovascular disease, autoimmune diseases, and more.

Figure. In Vivo Small Molecule Drugs Delivery. (Chung SL, et al.; 2021)

In vivo delivery of small molecule drugs faces several difficulties and challenges that may affect the effectiveness and safety of the drugs. The following are some common difficulties in in vivo delivery of small molecule drugs:

• Uneven biodistribution: uneven distribution of a drug in the body may cause some tissues or organs to receive more of the drug and other parts to receive less of the drug. This may reduce therapeutic efficacy or cause toxic effects.
• Metabolism and elimination: small molecule drugs often undergo metabolism, making them more easily excreted from the body. This may result in a shorter half-life of the drug, the need for frequent dosing, or the need to develop the metabolic stability of the drug.
• Cell membrane permeability: Drugs need to cross biological membranes, such as cell membranes, to reach their target site. Many small molecule drugs have limited cell membrane permeability and therefore need to be optimized for this issue.
• Drug-target affinity: The drug must have sufficient affinity to bind to the target protein to achieve a therapeutic effect. Different drug targets have different binding affinity requirements, which may require drug design and chemical modification.
• Drug interactions: small molecule drugs may interact with other molecules in the body, affecting their absorption, distribution, metabolism, and excretion. This interaction may result in adverse reactions or drug ineffectiveness.

In order to overcome the above shortcomings, CD BioSciences has developed an in vivo small molecule drugs delivery system using nanoparticles as carriers. The small molecule drugs encapsulated by our carrier has good stability, long half-life in vivo, obvious therapeutic effect, and low toxic and side effects of the drug.

CD BioSciences provides customized delivery strategies, through the precise design and modification of delivery vehicles, as well as advanced technology platforms, can help you solve the above problem.

Key Features

• Lipid Nanoparticles
• Polymer Nanoparticles
• Metal Nanoparticles
• Magnetic Nanoparticles
• Nanoemulsion
• Organic-Inorganic Hybrid Nanoparticles
• Polylactic Acid-Co-Polyethylene Glycol (Plga-Peg) Nanoparticles

Our Advantage:

• CD BioSciences can provide professional small molecule drugs in vivo delivery system to achieve efficient in vivo delivery;
• Our delivery system can add modified ligands to achieve targeting;
• The in vivo small molecule drugs delivery system has low toxicity to the body and is safe to use
• In vivo small molecule drugs delivery system carriers protect peptides from dilution and degradation during in vivo delivery
• The delivery system can achieve timing, location, fixed rate and targeted release in vivo, so that experimental animals have a long-lasting effect after a single injection
• The system load is high, and the delivery requirements of different doses can be fulfilled
• Professional design and service team to provide you with reliable service and technical support feedback technical report in time

You can expect timely feedback on technical reports.CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect in vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

Reference

1. Chung SL, et al.; Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment. Nanomaterials (Basel). 2021, 11(10):2467.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.